Drug delivery

#Drug delivery #Drug development #Rare disease

Sanofi makes access to essential medicines commitment

Sanofi CEO Paul Hudson has outlined key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. The company’s commitment is based on: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees. “The pandemic… Read More

#News

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Drug delivery #Drug development #Drug discovery #Research

Russian scientists’ to help create targeted drug delivery capsules

Scientists from MIPT and ITMO University and their colleagues have studied the formation and growth of crystals from simple organic molecules into large associations, which may help create capsules for targeted drug delivery to specific tissues in the human body. The scientific paper was published in the journal Crystal Growth… Read More

#News

#Drug candidates #Drug delivery #Drug development #Drug discovery #Gene therapy

Ilya’s ILP100 gene therapy speeds up healing by six days on average

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More

#News

#AstraZeneca #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

US trial data show Oxford-AstraZeneca vaccine is safe and 79% effective 

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biotechnology #Drug delivery #Drug development #Events

Join NanoTemper Technologies’ Prometheus Panta tour

NanoTemper Technologies will be running a case study and walk through of Prometheus Panta. Join the company on 30 March to learn how to make formulation workflow more efficient with multi-parameter stability characterisation. This event will provide new perspectives on data and will look at how running thermal unfolding, particle… Read More

#News

#Cell and gene therapy #Drug delivery #Gene therapy #Life sciences

£18m network of gene therapy hubs to be created in the UK

LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC), have announced three major investments totalling £18 million to create a network of gene therapy innovation hubs. The funding will support the creation of three facilities to advance the clinical development of… Read More

#Editor's Choice #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna starts vaccine trials on babies and children

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and… Read More

#Covid-19 #Editor's Choice #News

#Drug delivery #Drug development #Drug discovery

Horizon Therapeutics acquires Viela Bio

Discovery, development and commercialisation company Horizon Therapeutics has announced the completion of the acquisition of drug developer, Viela Bio. Tim Walbert, chairman, president and chief executive officer, Horizon, said: “With its deep, mid-stage biologics pipeline, strong R&D team and on-market medicine UPLIZNA, Viela is a strong complementary strategic fit with… Read More

#News

#Bayesian #Clinical trial #Drug delivery

New platform aims to simplify access to Bayesian clinical trial designs

Cytel, provider of statistical software and advanced analytics for clinical trial design and execution, has launched East Bayes, an web-based extension of the East platform that enables adoption of the most computationally intensive Bayesian clinical trial designs, without the need for powerful on-site computers. The launch expands East’s range of… Read More

#News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#Biopharmaceuticals #Biotechnology #Drug delivery #Drug development

Amryt and Medison distribution agreement for metreleptin in Canada

Global biopharmaceutical company Amryt has signed a distribution agreement with Medison Pharma Canada to distribute Myalepta (metreleptin) in Canada. Amryt is a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising novel treatments for rare diseases. Medison is a commercial partner of global biotech companies that provide integrated services… Read More

#News

#AstraZeneca #Biopharmaceuticals #Drug delivery #Drug development

Aptamer Group extends AstraZeneca collaboration

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers… Read More

#Editor's Choice #News #Trending News

#Biopharmaceutical #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

Novartis and CureVac sign COVID-19 vaccine candidate agreement

Novaratis has signed an initial agreement to manufacture biopharmaceutical company CureVac’s COVID-19 vaccine candidate, CVnCoV. Following final agreement, Novartis plans to start manufacturing of the mRNA and bulk drug product in the second quarter of 2021. It is anticipated to produce up to 50 million doses by the end of… Read More

#News

#Drug delivery

Researchers design tiny, star-shaped devices to deliver drugs more efficiently

Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body. David Gracias, a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins… Read More

#News